Annual report [Section 13 and 15(d), not S-K Item 405]

Commitments and Contingencies (Details)

Commitments and Contingencies (Details)									1 Months Ended			3 Months Ended		12 Months Ended
Commitments and Contingencies (Details)	Mar. 28, 2024 USD ($)	Mar. 27, 2024 USD ($)	Oct. 27, 2023 USD ($)	Jun. 21, 2021 USD ($)	May 28, 2021 USD ($)	Mar. 25, 2021 USD ($)	Feb. 03, 2020 USD ($)	Jul. 15, 2019 USD ($)	Oct. 31, 2024 USD ($)	Apr. 30, 2024 USD ($)	Jul. 31, 2019 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2020 USD ($) milestone	Dec. 31, 2024 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2018 unit $ / shares	Feb. 03, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 09, 2021 USD ($)
Loss Contingencies [Line Items]
Royalty agreement, payment received											$ 2,000,000
Period after public launch to terminate agreement											3 years
Buyout option, percentage of net present value of royalty payments											75.00%
Aevi
Loss Contingencies [Line Items]
Payment for contingent consideration														$ 0
AlmataBio Transaction
Loss Contingencies [Line Items]
Cash payments to acquire assets	$ 7,500,000									$ 7,500,000				7,500,000
Milestone payment due upon first patient dosed in a Phase 2 trial														5,000,000
Aevi
Loss Contingencies [Line Items]
Number of milestones \| milestone													2
Milestone payment due upon first patient dosed in a Phase 2 trial													$ 6,500,000
AVTX-301 Out-License
Loss Contingencies [Line Items]
Licensed product expiration term					10 years
Milestone One \| AlmataBio Transaction
Loss Contingencies [Line Items]
Contingent consideration	5,000,000
Milestone One \| Aevi
Loss Contingencies [Line Items]
Contingent consideration																	$ 2,000,000
Milestone Two \| AlmataBio Transaction
Loss Contingencies [Line Items]
Contingent consideration	$ 15,000,000
Milestone Two \| Aevi
Loss Contingencies [Line Items]
Contingent consideration																	$ 4,500,000
Milestone Three \| AVTX-009
Loss Contingencies [Line Items]
Collaborative agreement, milestone payment									$ 5,000,000
Lilly License Agreement \| AVTX-009 Lilly License Agreement
Loss Contingencies [Line Items]
Milestone payments		$ 70,000,000
Maximum aggregate milestone payment		$ 650,000,000
License agreement term		120 days
Research and development														0
Cumulative expense recognized to date														0
Lilly License Agreement \| AVTX-009 Lilly License Agreement \| Minimum
Loss Contingencies [Line Items]
License agreement royalties		5.00%
Lilly License Agreement \| AVTX-009 Lilly License Agreement \| Maximum
Loss Contingencies [Line Items]
License agreement royalties		15.00%
Kyowa Kirin Co., Ltd. (KKC) \| Minimum \| Contract Termination
Loss Contingencies [Line Items]
License agreement term						6 months
Kyowa Kirin Co., Ltd. (KKC) \| Maximum \| Contract Termination
Loss Contingencies [Line Items]
License agreement term						12 months
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement
Loss Contingencies [Line Items]
Upfront license fee						$ 10,000,000
Research and development														0
Cumulative expense recognized to date														0
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone One
Loss Contingencies [Line Items]
Maximum aggregate milestone payment						112,500,000
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone Two
Loss Contingencies [Line Items]
Maximum aggregate milestone payment						$ 75,000,000
CHOP License Agreement
Loss Contingencies [Line Items]
Collaborative arrangement, royalty term							15 years
CHOP License Agreement \| Contract Termination
Loss Contingencies [Line Items]
License agreement term							6 months
CHOP License Agreement \| AVTX-002 KKC License Agreement
Loss Contingencies [Line Items]
Maximum aggregate milestone payment														1,100,000
Upfront license fee							$ 500,000
Payments for legal settlements															$ 1,000,000
License fee							$ 200,000
Sanford Burnham Prebys Medical Discovery Institute \| Contract Termination
Loss Contingencies [Line Items]
License agreement term				90 days
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement
Loss Contingencies [Line Items]
Upfront license fee				$ 400,000
Research and development														0
Cumulative expense recognized to date														0
License fee				40,000														$ 100,000
Patent costs				500,000
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Milestone One
Loss Contingencies [Line Items]
Maximum aggregate milestone payment				24,200,000
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Milestone Two
Loss Contingencies [Line Items]
Maximum aggregate milestone payment				$ 50,000,000
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Minimum
Loss Contingencies [Line Items]
License agreement royalties				10.00%
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Maximum
Loss Contingencies [Line Items]
License agreement royalties				20.00%
Astellas Pharma, Inc. (Astellas)
Loss Contingencies [Line Items]
License agreement term								60 days
Astellas Pharma, Inc. (Astellas) \| AVTX-006
Loss Contingencies [Line Items]
Licensed product expiration term								10 years
Astellas Pharma, Inc. (Astellas) \| AVTX-006 Astellas License Agreement
Loss Contingencies [Line Items]
Maximum aggregate milestone payment								$ 5,500,000
Upfront license fee								$ 500,000
Research and development														0
Cumulative expense recognized to date														500,000
Alto \| AVTX-301 Out-License
Loss Contingencies [Line Items]
Maximum proceeds from milestones					$ 18,600,000
Revenue recognized from milestones to date														0
ES \| AVTX-406 License Assignment
Loss Contingencies [Line Items]
Revenue recognized from milestones to date														$ 0
ES \| Milestone One \| AVTX-406 License Assignment
Loss Contingencies [Line Items]
Maximum proceeds from milestones																			$ 6,000,000
ES \| Milestone Two \| AVTX-406 License Assignment
Loss Contingencies [Line Items]
Maximum proceeds from milestones																			$ 20,000,000
AUG Therapeutics, LLC \| Purchase Agreement
Loss Contingencies [Line Items]
Upfront payment paid												$ 200,000
Asset acquisition consideration transferred, liabilities												$ 400,000
AUG Therapeutics, LLC \| Purchase Agreement \| AVTX-800 Series Asset Sale
Loss Contingencies [Line Items]
Upfront payment paid			$ 200,000
Asset acquisition consideration transferred, liabilities			$ 400,000
Contingent milestone upfront payment percentage			0.20
Contingent milestone payment			$ 15,000,000
Maximum potential payments			$ 45,000,000
TRIS Pharma \| Karbinal Agreement
Loss Contingencies [Line Items]
Minimum quantity required \| unit																70,000
Make whole payment per unit (in dollars per share) \| $ / shares																$ 30